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Abstract
Demyelination is the cause of disability in various neurological disorders. It is therefore crucial to understand the molecular
regulation of oligodendrocytes, the myelin forming cells in the CNS. Growth factors are known to be essential for the
development and maintenance of oligodendrocytes and are involved in the regulation of glial responses in various
pathological conditions. We employed the well established murine cuprizone model of toxic demyelination to analyze the
expression of 13 growth factors in the CNS during de- and remyelination. The temporal mRNA expression profile during
demyelination and the subsequent remyelination were analyzed separately in the corpus callosum and cerebral cortex
using laser microdissection and real-time PCR techniques. During demyelination a similar pattern of growth factor mRNA
expression was observed in both areas with a strong up-regulation of NRG1 and GDNF and a slight increase of CNTF in the
first week of cuprizone treatment. HGF, FGF-2, LIF, IGF-I, and TGF-ß1 were up-regulated mainly during peak demyelination.
In contrast, during remyelination there were regional differences in growth factor mRNA expression levels. GDNF, CNTF,
HGF, FGF-2, and BDNF were elevated in the corpus callosum but not in the cortex, suggesting tissue differences in the
molecular regulation of remyelination in the white and grey matter. To clarify the cellular source we isolated microglia from
the cuprizone lesions. GDNF, IGF-1, and FGF mRNA were detected in the microglial fraction with a temporal pattern
corresponding to that from whole tissue PCR. In addition, immunohistochemical analysis revealed IGF-1 protein expression
also in the reactive astrocytes. CNTF was located in astrocytes. This study identified seven different temporal expression
patterns for growth factors in white and grey matter and demonstrated the importance of early tissue priming and exact
orchestration of different steps during callosal and cortical de- and remyelination.
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Introduction
In demyelinating diseases of the central nervous system (CNS)
like multiple sclerosis (MS) and the leukodystrophies, repair
mechanisms and remyelination fail leading to neurological
impairment. Regenerative therapies in these diseases are currently
not available, thus the understanding of the molecular events
during de- and remyelination is necessary to develop new
treatment strategies. In recent years a number of growth factors
(GFs) has been characterized to be involved in the pathology of
MS [1,2]. Neurotrophins, neuropoietic cytokines, and other
growth factors are suggested to support migration, proliferation,
and differentiation of glial cells and to regulate myelin synthesis
[3,4,5]. A disturbed balance of interacting GFs that regulate
differentiation of oligodendrocytes and onset of myelination may
contribute to the limited remyelination of MS plaques [6,7].
However, the detailed expression pattern of GF expression during
de- and remyelination is not available. Based on in vitro and in vivo
studies basic fibroblast growth factor (FGF-2) and platelet-derived
growth factor alpha (PDGF-A) are postulated to promote
proliferation and to inhibit differentiation of oligodendrocyte
precursor cells (OPCs) [8,9,10,11]. In contrast, insulin-like growth
factor I (IGF-I), ciliary neurotrophic factor (CNTF), and
transforming growth factor-beta 1 (TGF-ß1) are considered to
be key modulators of oligodendrocyte differentiation and myeli-
nation [12,13,14,15,16,17,18]. Leukemia inhibitory factor (LIF)
and CNTF are known to promote survival of oligodendrocytes
[19]. Since cortical MS lesions are associated with an intact blood
brain barrier (BBB), alleviated infiltration of lymphocytes, mild
astrogliosis [20,21], and a more extensive remyelination capacity
[22] the underlying pathophysiological mechanisms for de- and
remyelination seem to differ between white and grey matter.
Knowledge of the exact regulation and requirements for GF
expression during remyelination may allow the design of specific
regenerative treatments for demyelinating diseases.
The murine cuprizone model is well established to study
experimental de- and remyelination. Cuprizone feeding leads to
oligodendrocyte death and a subsequent reversible demyelination
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reliable and nearly complete remyelination in this model allows to
study the mechanisms that lead to successful regeneration. In
addition the temporal course and dynamics of de- and remyelina-
tion differ in cerebellar and cerebral white and grey matter thus
allowing the investigation of regional differences [25]. The aim of
this study was to identify key GFs, which are involved in de- and
remyelination in CNS white and grey matter.
Materials and Methods
Animals, induction of demyelination, tissue preparation
C57BL/6 male mice were obtained from Charles River
(Sulzfeld, Germany). Animals underwent routine cage mainte-
nance once a week and were microbiologically monitored
according to Federation of European Laboratory Animal Science
Associations recommendations [26]. Food and water were
available ad libitum. All research and animal care procedures were
approved by the Review Board for the Care of Animal Subjects of
the district government (Lower Saxony, Germany, approval ID
509.6-42502-03/671 and 33.9-42502-04-07/1309) and performed
according to international guidelines on the use of laboratory
animals.
Demyelination was induced in 8-week-old male C57BL/6 mice
by feeding with 0.2% cuprizone (bis-cyclohexanone oxaldihydra-
zone, Sigma-Aldrich Inc., USA) mixed into a ground standard
rodent chow for 4.5 weeks. For remyelination animals were
returned to normal chow for an additional 1.5 week.
Tissue preparation
At different time points (weeks 1, 2, 3, 3.5, 4, and 4.5 for
demyelination; weeks 5, 5.5, and 6 for remyelination) mice were
sacrificed and perfused via left cardiac ventricle with RNase free
phosphate buffered saline (PBS) for gene expression analysis or
with 4% paraformaldehyde (PFA) in phosphate buffer (PBS) for
immunohistochemistry. A group size of four or five animals was
investigated at each time point. For gene expression analysis the
brains were removed and immediately embedded in Tissue TekH
Compound (Sacura, USA), frozen in liquid nitrogen and stored at
280uC until use. Under RNase free conditions, serial coronal
sections (bregma +0.98 to 22.46) [27] with a thickness of 30 mm
were cut at 220uC. The sections were mounted on polyethylene-
naphthalate (PEN) membrane slides (Carl Zeiss MicroImaging
GmbH, Germany), fixed for 2 min in 70% ice-cold ethanol, rinsed
with DEPC (diethylpyrocarbonat) treated water, and stained for
30 s in 1% cresyl violet acetate solution (Sigma-Aldrich, Germany)
in 50% ethanol. Afterwards, sections were dehydrated in graded
ethanol series (70% and 100% ethanol) and finally air dried for
several minutes. All solutions were prepared with DEPC treated
water.
For immunohistochemistry brains were postfixed in 4% PFA in
PBS at 4uC overnight and paraffin embedded. For light
microscopy, 7 mm serial paraffin sections were cut and dried at
37uC overnight. Sections between bregma 20.70 mm and
21.46 mm according to mouse atlas [27] were analysed.
Laser microdissection
The PalmH MicroBeam System (Carl Zeiss MicroImaging
GmbH, Germany) was used to precisely excise the cerebral cortex
and medial part of the corpus callosum from coronal brain sections
of treated and age matched control mice (see supporting Fig. S1).
Dissected brain regions of the corpus callosum and cortex were
collected separately with a sterile 21-gauge needle and stored at
280uC until RNA extraction.
RNA isolation and quantitative RT-PCR
According to the manufacturer’s recommendations total RNA
was extracted from the microdissected cortex and corpus callosum
tissue using the RNeasyHMini Kit (Qiagen, Germany) and
RNeasyH Micro Kit (Qiagen, Germany), respectively. The RNA
concentration was measured with a NanoDrop 1000 spectropho-
tometer (Thermo Fisher Scientific, USA). cDNA was synthesized
using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, USA). RNA samples from cuprizone treated
and age matched control mice (cortex n=4, corpus callosum
n=5) were processed in parallel under the same conditions. Real-
time PCR analysis was performed using the StepOne
TM Real-
Time PCR System and appropriate TaqMan assays (Applied
Biosystems, USA). All primers were intron-spanning (see support-
ing Table S1). A negative control containing PCR amplification
mix without reverse transcribed cDNA template was included for
each PCR plate. Gene expressions of nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-
3), ciliary neurotrophic factor (CNTF), insulin-like growth factor I
(IGF-I), neuregulin 1 (NRG1), epidermal growth factor (EGF),
basic fibroblast growth factor (FGF-2), glial cell-derived neuro-
trophic factor (GDNF), platelet-derived growth factor alpha
(PDGF-A), leukemia inhibitory factor (LIF), hepatocyte growth
factor (HGF), and transforming growth factor-beta 1 (TGF-ß1)
were analysed in the corpus callosum and cortex at 9 time points
(demyelination phase: weeks 1, 2, 3, 3.5, 4, and 4.5; remyelination
phase: weeks 5, 5.5, and 6). The DDCt method was used to
determine differences in expression between cuprizone treated and
age-matched control mice. Changes in mRNA expression level
were calculated after normalization to hypoxanthin phosphoribo-
syltransferase (HPRT).
Isolation of microglia
Corpus callosum and cerebral cortex were dissected from whole
brains under a binocular microscope using ultra fine blades.
Isolation of microglia was performed based on previously
published protocols [28,29,30]. For mechanical dissociation,
cortex and corpus callosum were grinded separately through a
tissue homogenizer (Neolab, Germany) and triturated using
pasteur pipettes of decreasing diameter. Afterwards the cell
suspension was filtered through a 60 mm cell strainer (Millipore,
USA). For separation of microglia, cells were pelleted and
resuspended in 3.3 ml ice-cold 70% percoll (GE healthcare,
Sweden). The 70% percoll was overlayered with 5 ml 35% ice-
cold percoll and 3 ml ice-cold PBS. Density gradient centrifuga-
tion was performed at 800 g without brake for 25 minutes at 4uC.
After centrifugation the myelin containing 0/35 interface was
discarded and the microglia containing 35/70 interface was
collected and washed with ice-cold PBS.
Immunohistochemistry
For immunohistochemistry, paraffin embedded sections were
de-waxed, re-hydrated, and microwaved for 5 min in 10 mM
citrate buffer (pH 6.0), then blocked for 1 h with PBS containing
3% normal goat serum, 0.1% Triton X-100, and incubated with
primary antibody at 4uC overnight. The following primary
antibodies were used for myelin proteins: proteolipid protein
(PLP) (1:500, mouse IgG2a, Serotec, Germany) and myelin basic
protein (MBP) (1:500, mouse IgG2b, Covance, USA). Anti Nogo-
A (1:750, rabbit polyclonal, Millipore, USA) was used as a marker
for mature oligodendrocytes. Activated microglia were detected
using lectin ricinus communis agglutinin 1 (RCA-1) (1:1000,
fluorescein coupled, Vector Laboratories, USA). Glial fibrillary
acidic protein (GFAP) (1:200, mouse IgG1, Millipore, USA or
Growth Factors during De- and Remyelination
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marker for astrocytes. Nestin (1:200, mouse IgG1, Millipore, USA)
was selected to mark neural precursors. Cellular sources of the
following growth factors were analysed: CNTF (1:200, mouse
IgG1; Millipore, USA) and IGF-1 (1:200, mouse IgG1; Millipore,
USA). For immunofluorescent double staining the following pairs
of primary antibodies were used: CNTF/GFAP, IGF-1/GFAP,
Nestin/GFAP. Sections were then incubated for 1 h with the
secondary antibodies: goat anti-mouse IgG H+L Alexa-555/
Alexa-488 conjugated (1:500, Molecular Probes, USA) or/and
goat anti-rabbit IgG H+L Alexa-555/Alexa-488 conjugated.
Slides were mounted with Mowiol (Calbiochem, USA) containing
496-diamidino-2-phenylindole (DAPI; Invitrogen, USA).
Determination of de- and remyelination in the cortex and
corpus callosum
The extent of cortical demyelination was studied as described
previously [24]. In particular, myelin protein-stained sections for
PLP and MBP were scored using a light microscope (Olympus DP
72, Germany). Scoring of myelin was performed by three blinded
observers, using a scale from 0 (complete lack of myelin) to 4
(normal myelin). For determination of myelination in the corpus
callosum PLP and MBP stained sections were scored on a scale
from 0 (complete demyelination) to 3 (normal myelin) under the
same conditions [31].
Statistical analysis
Statistical analysis was performed using one-way analysis of
variance (ANOVA) followed by the Fisher-PLSD-test or Dunnett
test for post hoc comparison. LIF mRNA was not detected in the
control animals in both the corpus callosum and the cortex. The
normalization for LIF was done with the data from week 6. All
data are given as arithmetic means 6 standard error of the mean
(SEM). P values of the different ANOVAs are given in the results,
while group comparisons derived from post hoc analysis are
provided in the figures. In the latter cases, significant effects are
indicated by asterisks (compared to the preceding time point) or
rhombs (compared to control; *
#p,0.05; **
##p,0.01;
***
###p,0.001).
Results
De- and remyelination induced by cuprizone feeding
To determine de- and remyelination pattern in response to
cuprizone treatment, immunohistochemical stainings and real-
time PCR analyses for the myelin proteins PLP and MBP were
performed. As demonstrated in figure 1, maximal loss of MBP
(Fig. 1C, L) and PLP (Fig. 2D) is present in the corpus callosum
after 4.5 weeks of cuprizone feeding (for both myelin proteins
p,0.0001). At week 6 (after 1.5 week of normal diet), the
immunoreactivity for both MBP (Fig. 1C, N) and PLP (Fig. 1D)
was nearly completely recovered in the corpus callosum. The
mRNA expression for MBP and PLP was strongly down-regulated
already after 1 week and remained at low levels during the
following weeks of cuprizone treatment (for both p,0.0001)
(Fig. 1G, H). After cuprizone withdrawal from the diet, MBP and
PLP mRNA expression returned to normal levels (Fig. 1G, H).
In the cortex, the most severe loss of MBP and PLP was
detected at week 5 (p,0.0001) (Fig. 1E, F, Q). The mRNA
expression of MBP and PLP was strongly decreased after one week
and remained down-regulated during the whole cuprizone feeding
(for both p,0.0001) (Fig. 1I, J). The normalisation of mRNA
expression for MBP and PLP was achieved at weeks 5.5 and 6,
0.5–1 week later than in the corpus callosum.
Glial reactions during cuprizone treatment
To follow the oligodendroglial cellular response to cuprizone
feeding we used the marker Nogo-A. After 4.5 weeks of cuprizone
treatment Nogo-A positive cells were detected neither in the
medial corpus callosum nor in the cortex (Fig. 1T, X). At week 5
mature oligodendrocytes reappeared in the corpus callosum
(Fig. 1U). In the cortex, Nogo-A positive cells were seen only
sporadically at week 5 (Fig. 1Y). At weeks 5.5 and 6 the amount of
Nogo-A positive cells further increased in both areas (Fig. 1V, Z).
Accumulation of activated microglia was studied by RCA-1
staining (see supporting Fig. S2). In the corpus callosum RCA-1
positive cells were detected already after 2 weeks of cuprizone
feeding. During the following 2.5 weeks the amount of activated
microglia increased steadily and reached a peak at week 4.5
concomitant with the demyelination peak. Thereafter, a contin-
uous decrease of activated microglia was observed. In the cortex,
microgliosis occurred in an obviously reduced density as compared
to the corpus callosum. Within the cortex an infiltration of
activated microglia was found at weeks 3–5. At week 6 microglia
were only sporadically found in the cortex in the 6
th cellular layer.
Astrogliosis was studied by GFAP immunostaining (see
supporting Fig. S2). Consistent to our previous results [25], few
GFAP positive astrocytes were seen in the corpus callosum in
untreated controls, while in the cortex GFAP positive astrocytes
were found sporadically. After 2 weeks of cuprizone treatment a
strong astrogliosis occurred in the cortex. In the corpus callosum
strong astrogliosis was observed with a delay of one week as
compared to cortex. In both regions astrogliosis was detectable in
the following weeks until week 6.
Nestin positive cells were detected in the cortex at week 2
(Fig. 2G). These cells showed astrocytic shape and were double
positive for the astrocytic marker GFAP (Fig. 2C). Interestingly,
nestin positive cells were situated mostly in the fourth cellular layer
of the cortex. At the following weeks nestin positive cells were
sporadically seen in the cortex, mainly in the fifth and sixth cellular
level. In the corpus callosum nestin positive cells occurred only
sporadically at week 2. The main amount of these cells was
observed at weeks 3 (Fig. 2H), 4, and 4.5 followed by a gradual
decrease. Again, these cells showed astrocytic shape and were
double positive for the astrocytic marker, GFAP (Fig. 2D).
Analysis of growth factor mRNA expression profiles
during de- and remyelination in the corpus callosum and
cortex
To identify growth factors produced in the white and grey
matter during de- and remyelination, mRNA expression of
thirteen growth factors was studied in the medial corpus callosum
and the lateral cerebral cortex. The individual profiles of each
growth factor mRNA expression in the white and grey matter are
shown in figures 3, 4, and 5.
NRG1 and GDNF mRNA expression was massively up-
regulated after the first week of cuprizone feeding in both the
corpus callosum and cortex (for both p,0.0001). During the
following weeks NRG1 and GDNF mRNA expression normalized
(Fig. 3C, D, E, F). At the onset of remyelination, there was a trend
for an increased amount of GDNF mRNA expression in the
corpus callosum that failed to be significant.
CNTF and EGF mRNA production showed significant changes
mostly in the white matter (corpus callosum: for both p,0.0001;
cortex: for CNTF p=0.01; EGF p=0.05). Both factors were
slightly up-regulated after the first week of cuprizone feeding
(CNTF - 4 times in the corpus callosum and 2.5 times in the
cortex; EGF - 2.5 times in the corpus callosum and 3.6 times in the
Growth Factors during De- and Remyelination
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22623Figure 1. Demyelination and remyelination in the corpus callosum and the cortex. The red marked areas present the investigated middle
part of the corpus callosum (A) and cortex in (B). C, D) MBP and PLP myelin protein expression in the corpus callosum. Score 0 represents complete
myelin protein loss while score 3 represents normal myelination. E, F) MBP and PLP myelin protein expression in the cortex. Score 0 represents
complete myelin loss; score of 4 shows normal myelination. G, H) mRNA expression of MBP and PLP in the corpus callosum. I, J) mRNA expression of
MBP and PLP in the cortex. K–N) MBP stained sections demonstrate severe demyelination in the corpus callosum (cc) at week 4.5. Remyelination
starts already at the week 5 and is almost complete at week 6. O–R) MBP stained sections show severe demyelination in the cortex (ctx) at weeks 4.5,
and 5. At week 6 the MBP amount increases (MBP is shown in red, nuclear staining with DAPI in blue). Representative sections show Nogo-A positive
oligodendrocytes in the corpus callosum (cc) (S–V) and cortex (ctx) (W–Z). No oligodendrocytes are seen in the corpus callosum and cortex at week
4.5 (T, X). Oligodendrocytes reappear at week 5 in both, the corpus callosum and cortex (U, Y) (Nogo-A is shown in red, nuclear staining with DAPI in
blue).
doi:10.1371/journal.pone.0022623.g001
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were strongly elevated only in the white matter (Fig. 3G, H, I, J).
TGF-ß1 and IGF-1 mRNA expression increased significantly
after cuprizone treatment and reached their peak after 4.5 weeks
at peak demyelination in both investigated areas (for both
p,0.0001). With progressing remyelination, mRNA expression
of these two factors decreased gradually (Fig. 4C, D, E, F).
The mRNA synthesis of HGF and FGF-2 was strongly
regulated in both white and grey matter during the whole
experimental time window (corpus callosum: for both factors
p,0.0001; cortex: FGF-2 p,0.0001; HGF p=0.05) (Fig. 4G, H,
I, J). Whereas in the cortex FGF-2 mRNA was increased at a
constant level during the whole demyelination, in the corpus
callosum there was a peak of mRNA elevation at weeks 4 and 4.5.
During remyelination the mRNA of HGF and FGF-2 continued
to be elevated in the corpus callosum. In contrast, in the cortex the
mRNA expression of these two factors was comparable to control
levels.
The mRNA expression of NT-3 and NGF decreased signifi-
cantly upon cuprizone treatment (for both p,0.0001) in the
corpus callosum (Fig. 5C, E). With the cessation of the cuprizone
diet NT-3 and NGF mRNA expression returned to normal levels.
BDNF mRNA synthesis was only slightly elevated in the corpus
callosum during the first 3.5 weeks of cuprizone feeding, and
normalized within the following weeks. During remyelination the
mRNA expression of BDNF increased significantly (p=0.001) in
the corpus callosum (Fig. 5G).
In the cortex, the mRNA expression of NT-3, NGF, and BDNF
did not change significantly and persisted on levels comparable to
controls during both de- and remyelination (Fig. 5D, F, H).
Figure 2. Astrocytic expression of nestin during early demyelination in the corpus callosum and the cortex. The red marked areas
represent the investigated medial corpus callosum (A) and parts of lateral cortex (B). Nestin positive cells (in green) are present at week 2 in the
cortex (G) and at week 3 in the corpus callosum (H). GFAP stained activated astrocytes (in red) are numerously present at week 2 of the cuprizone
diet in the cortex (E) and at week 3 in the corpus callosum (F). Several nestin positive cells are double positive for GFAP in both the cortex (C) and the
corpus callosum (D) (Nestin is shown in green, GFAP in red, nuclear staining with DAPI in blue).
doi:10.1371/journal.pone.0022623.g002
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22623Figure 3. Expression of growth factor mRNA in the corpus callosum and cortex of mice undergoing demyelination / remyelination.
The red marked areas present the investigated middle part of the corpus callosum in A and cortex in B. C–J) Graphs show mRNA expression fold
changes of NRG1, GDNF, CNTF, and EGF mRNA expression in the corpus callosum (C–I) and in the cortex (D–J) compared to age-matched controls
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remyelination in both regions (Fig. 5I, J).
The expression of LIF mRNA was hardly detectable in both the
corpus callosum and the cortex of control mice. Thus, these
mRNA expressions were calculated in comparison to the mRNA
expression at week 6. In the white matter, LIF mRNA was
particularly increased at the weeks 2 and 3 of cuprizone feeding
(p=0.005) (Fig. 5K). In the grey matter, LIF mRNA synthesis was
strongly increased during the first weeks (p=0.002) and at the
peak of demyelination (Fig. 5L).
Seven different temporal patterns of growth factor
mRNA expression are identified in the white and grey
matter
In order to summarise the data, we identified 7 different
temporal pattern of mRNA expression for all studied growth
factors in the white and grey matter (Fig. 6).
Pattern 1: The mRNA expression was strongly up-regulated
during the first two weeks and is nearly at control level during the
following weeks of de-and remyelination. This pattern was typical
for GDNF and NRG1 mRNA expression in both white and grey
matter (Fig. 6A).
Pattern 2: The mRNA expression was increased during the
whole demyelination phase and normalises with the onset of
remyelination. This pattern was identified only in the cortex for
FGF-2, HGF, and LIF (Fig. 6B).
Pattern 3: The mRNA expression was elevated during early
demyelination (1–3 weeks of cuprizone feeding), then returns to
control levels and has a second peak up-regulation during
remyelination. This pattern was characteristic for CNTF and
BDNF in the corpus callosum (Fig. 6C).
Pattern 4: The mRNA expression was up-regulated only
between weeks 2 and 3.5. This pattern was seen only for LIF in
the corpus callosum (Fig. 6D).
Pattern 5: mRNA expression increased gradually during the
whole demyelination period reaching its maximum at the peak of
demyelination followed by a decline during remyelination. This
pattern was characteristic for IGF-1 and TGF-ß1 in the white and
grey matter (Fig. 6E).
Pattern 6: mRNA expression increased during late demyelin-
ation and stays elevated during remyelination. This pattern was
determined for FGF-2 and HGF in the corpus callosum (Fig. 6F).
Pattern 7: mRNA expression was down-regulated during peak
demyelination and normalised after the onset of remyelination.
This pattern was identified for NT-3 and NGF in the corpus
callosum (Fig. 6G).
mRNA expression of GDNF, IGF-1 and FGF-2 was elevated
in the microglia fraction
To clarify whether microglia could provide growth factors
relevant for the regulation of cuprizone induced de- and
remyelination, we analysed the expression of IGF-1, TGF-ß1,
FGF-2, BDNF, GDNF, and CNTF by quantitative PCR after
isolation of microglia from cortex and corpus callosum. The
expression of growth factors was measured in microglia isolated
from untreated mice and cuprizone treated mice after 1, 3.5, 4.5,
5.5, and 6 weeks. The GDNF mRNA expression was strongly
elevated only after the first week of cuprizone feeding in both the
corpus callosum and the cortex (Fig. 7C, D). A strong up-
regulation of IGF-1 was found in cortical and callosal microglia
reaching a maximum after 3.5–4.5 weeks. During remyelination,
the expression of IGF-1 was further up-regulated in both the white
and grey matter showing however a tendency to decline. The
FGF-2 mRNA expression was slightly elevated during demyelin-
ation in the cortex (Fig. 7D). In the corpus callosum, FGF-2
mRNA expression reached its maximum during severe demyelin-
ation after 3.5 weeks of cuprizone feeding (Fig. 7C) and decreased
after the onset of remyelination. The expression of BDNF and
CNTF was neither changed in the cortex nor in the corpus
callosum (Fig. 7C, D).
IGF-1 and CNTF are produced in astrocytes
Immunochemical stainings for IGF-1 and CNTF were per-
formed in order to identify the cellular source of these growth
factors. The cells producing IGF-1 as well CNTF showed
astrocytic shape. The double stainings with GFAP confirmed the
astrocytic localisation of these growth factors (Fig. 7E–H).
Discussion
Growth factors are involved in the orchestration of proliferation,
migration, and differentiation of glial cells in demyelinating
diseases and are suggested to support remyelination in the CNS.
Using the murine cuprizone model of toxic demyelination we
analysed the expression of various neurotrophic factors during
demyelination and the subsequent remyelination in the white and
the grey matter and identified seven different temporal expressions
pattern.
After one week of cuprizone feeding mature oligodendrocytes
become apoptotic [32], while after four weeks they are nearly
completely depleted. As a consequence of this we observed a
severe loss of myelin proteins in both the corpus callosum and
cortex. Thereafter, oligodendrocytes began to reappear. The
temporal myelination pattern was different between corpus
callosum and cortex and the maximum of demyelination occurred
delayed in the cortex, as previously described [25]. Subsequently,
cortical reexpression of myelin proteins was also delayed. Along
with demyelination, microglial infiltration and astrogliosis were
observed in both regions.
Since exogenous CNTF induces reactive astrogliosis and the up-
regulation of GFAP mRNA [33], CNTF has been suggested to be
a key player in astrogliosis. In our work CNTF mRNA expression
was up-regulated in the first two weeks of cuprizone feeding in
both the corpus callosum and cortex and may account for the
astrogliosis. Interestingly, GDNF and NRG1 were strongly up-
regulated in the white and grey matter at the first two weeks of
cuprizone feeding, when demyelination was not yet detectable.
GDNF was shown to be up-regulated in astrocytes during various
pathophysiological conditions [34,35,36] and proliferative effects
on C6 glioma cells [37] have been demonstrated. Thus, the up-
regulation of GDNF may provide an activating signal for
astrocytes. Furthermore, GDNF was also shown to stimulate
microglial activation and to be produced by microglia [38,39,40].
In our study microglia were identified as the source of GDNF but
not NRG1. Activated microglia were first seen after 2 weeks of
cuprizone feeding in both corpus callosum and cortex. There was
an up-regulation of LIF mRNA at weeks 2–3 in the corpus
callosum, while in the cortex LIF was continuously up-regulated
during the whole demyelination phase. Since LIF is known to
and normalized with HPTR using the DDCt method. Significant changes are indicated by rhombs (compared to control) or asterisks (compared to the
preceding time point) (*
#p,0.05; **
##p,0.01; ***
###p,0.001).
doi:10.1371/journal.pone.0022623.g003
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remyelination. The red marked areas present the investigated middle part of the corpus callosum (A) and the cortex (B). C–J) Graphs show mRNA
expression fold changes of TGF-ß1, IGF-1, HGF, and FGF-2 mRNA expression in the corpus callosum (C–I) and in the cortex (D–J) compared to the
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proliferation, activation, and migration of microglia/macrophages
and stimulates the phagocytosis of myelin debris [41,42,43] we
hypothesise that LIF may also modulates microglial activity in this
model.
IGF-1 and TGF-ß1 mRNA expression were similar in both
studied regions and showed a gradual elevation during demyelin-
ation with a peak at week 4.5 followed by a gradual decrease
during remyelination. These results are in line with data generated
in other models of experimental demyelination [44,45] and in
cuprizone induced demyelination [46]. However, in our study the
expression of IGF-1 was examined separately in the corpus
callosum and the cortex, whereas Mason et al. studied tissue from
whole brains. In addition, we investigated the source of IGF-1
mRNA expression and found an elevation of IGF-1 expression in
both microglia and in reactive astrocytes.
In the cortex an increased expression of FGF-2 and HGF
mRNA was observed during demyelination, which returned to
normal levels during remyelination. In contrast, in the corpus
callosum an elevated expression of FGF-2 and HGF mRNA
persisted during remyelination. Microglia were identified as a
source of FGF-2. It is widely accepted that the main impact of
FGF-2 is the support of OPC proliferation [8] and inhibition of
progenitor differentiation/myelination [47,48]. Using in situ-
hybridization methods, FGF-2 has been shown to be up-regulated
after 6 weeks of 0.3% cuprizone feeding in the corpus callosum
[10]. It should be noted that the treatment with 0.3% cuprizone
induces a different demyelination pattern as compared to 0.2%
cuprizone (31). In our study mice were fed with 0.2% cuprizone
and we found a strong up-regulation of FGF-2 mRNA after 4.5
weeks (timepoint of maximal myelin loss) corresponding to the
intensive proliferation of OPCs. It has been shown previously that
the absence of FGF-2 promotes regeneration of oligodendrocytes
after cuprizone induced demyelination [10]. We therefore assume
that the down-regulation of FGF-2 in the cortex allows OPC
differentiation and subsequent myelin formation. However, in the
corpus callosum a different expression of FGF-2 was observed. An
up-regulation of FGF-2 during remyelination has also been found
in lysolecithin induced demyelination [44] as well as in vitro in
myelinating aggregate cultures [49]. It can only be speculated that
FGF-2 possesses multiple functions and acts not only directly on
oligodendrocytes but also influences other cell types promoting
myelination indirectly. Moreover, different splice variants of FGF-
2 could have different modes of actions or FGF-2 could act
through different receptors.
age-matched controls and normalized with HPRT using the DDCt method. Significant effects are indicated by rhombs (compared to control) or
asterisks (compared to the preceding time point) (*
#p,0.05; **
##p,0.01; ***
###p,0.001).
doi:10.1371/journal.pone.0022623.g004
Figure 5. Expression of growth factor mRNA in the corpus
callosum and the cortex of mice undergoing demyelination /
remyelination. The red marked areas present the investigated middle
part of the corpus callosum (A) and the cortex (B). C–L) Graphs show
mRNA expression fold changes of NT-3, NGF, BDNF, PDGF-A, and LIF
mRNA expression in the corpus callosum (C–K) and in the cortex (D–L)
compared to the age-matched controls and normalized with HPRT
using the DDCt method. Significant effects versus controls are indicated
by rhombs or asterisks if compared to the preceding time point
(*
#p,0.05; **
##p,0.01; ***
###p,0.001).
doi:10.1371/journal.pone.0022623.g005
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functional HGF/c-Met system, which can influence the prolifer-
ation, development, and cytoskeletal organization, is present in
oligodendrocytes [50,51]. HGF producing microglia/macrophag-
es were present in EAE lesions during the recovery phase, but not
in the acute stage of disease [51], suggesting to play a role in
remyelination.
Interestingly, CNTF and BDNF showed a second peak in
mRNA expression at the onset of remyelination in the corpus
callosum, but not in the cortex. CNTF has been detected in
astrocytes in the remyelinating phase after viral-induced spinal
cord demyelination [52]. In contrast, in the lysolecithin model
CNTF mRNA expression was not up-regulated during remyeli-
nation [44]. The conflicting results of CNTF expression in
different demyelination models and CNS regions may be due to
the heterogeneity of OPC populations and involvement of
peripheral inflammatory cells. In our study CNTF mRNA up-
regulation corresponded with the elevation of MBP and PLP
mRNA expression in the corpus callosum. We hypothesize that
CNTF may promote remyelination of the corpus callosum but
Figure 6. Different temporal pattern of growth factors mRNA expression. A) Pattern 1: characteristic for NRG1 and GDNF mRNA expression
in the corpus callosum and the cortex. B) Pattern 2: characteristic for FGF-2, HGF, and LIF mRNA expression in the cortex. C) Pattern 3: characteristic
for CNTF, BDNF mRNA expression in the corpus callosum. D) Pattern 4: characteristic for LIF mRNA expression in the corpus callosum. E) Pattern 5:
characteristic for IGF-1 and TGF-ß1 mRNA expression in both the corpus callosum and the cortex. F) Pattern 6: characteristic for FGF-2 and HGF mRNA
expression in white matter. G) Pattern 7: characteristic for NGF and NT-3 mRNA expression in the corpus callosum.
doi:10.1371/journal.pone.0022623.g006
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differentiation in optic nerve, but it is not supportive for
differentiation of cortical OPCs [53]. In addition, CNTF and
CNTF receptor alpha expression patterns differ between white
and grey matter astrocytes [54]. This may be again due to the
heterogeneity of astrocytes and OPCs in different CNS areas.
Since cortical OPCs do not express the full-length BDNF
receptor, trkB, BDNF can not promote differentiation of cortical
oligodendrocytes [55]. Probably, cortical OPCs do not require
BDNF support for differentiation, which could explain the
observed differences in BDNF mRNA expression between the
white and grey matter.
Figure 7. Glial localization of growth factor production. The expression of the growth factors IGF-1, FGF-2, CNTF, GDNF, BDNF, and TGF-ß1
was analysed in microglia by real-time PCR. Microglia were isolated from the cortex (ctx) and corpus callosum (cc) and RNA was extracted from the
controls and cuprizone treated mice after 1, 3, 4.5, 5.5, and 6 weeks. Fold changes of mRNA levels of the different growth factors are presented after
normalization to HPRT and compared to the expression of untreated mice (=1, showed by the dotted line). Representative pictures show the CNTF
(red) expression by GFAP (green) expressing astrocytes in the cortex at the week 2. Double positive cells are yellow (E, F). Representative pictures
show the IGF-1 (red) expression by GFAP (green) expressing astrocytes in the corpus callosum at week 4.5 (G, H).
doi:10.1371/journal.pone.0022623.g007
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down-regulated during demyelination and restored at the onset of
remyelination in the corpus callosum. The mRNA expression of
all analysed neurotrophins did not change during the whole
experiment, indicating that these neurotrophins do not to play a
crucial role during de- or remyelination in the cortex. NT-4 was
not detected in both areas, neither during de- nor during
remyelination.
Taking our results and the published data in consideration, the
following scenario of de- and remyelination orchestration in the
corpus callosum and cortex could be suggested: Demyelination is
initiated already after 1 week of cuprizone feeding. NRG1,
GDNF, and CNTF are suggested to induce astrogliosis and
microgliosis. In turn, reactive astrocytes produce LIF that further
stimulates migration, activation, and proliferation of microglia.
Activated microglia and reactive astroglia prepare remyelination
by the release of IGF-1, FGF-2, and HGF, which support
migration, proliferation, and differentiation of OPCs. CNTF,
FGF-2, BDNF, and HGF are suggested to be the key player in
promoting remyelination in the corpus callosum. In the cortex,
these latter factors may not be required or act in different time
windows.
Interestingly, some growth factors showed similar temporal
expression pattern arguing for either a synergetic mode of action or
for a certain degree of redundancy. According to the temporal
expression profile we could identify seven different pattern of
mRNA expression in the white and grey matter. These patterns
demonstrate the requirement of different factors during the various
stages of de- and remyelination to achieve successful repair. It is
likely that this orchestration of repair promoting factors follows a
strict pattern since this can also be observed in the lysolecithin
model of demyelination, in particular for IGF-1, FGF-2, TGF-ß1
[44]. Hence,it seems unlikely that our results represent a cuprizone-
specific epiphenomenon. However, since demyelination occurs
rapidly in the lysolecithin model there is no early priming of the
lesions as in the cuprizone model demonstrated here.
In conclusion, this detailed longitudinal analysis of GF
expression during de- and remyelination reveals seven different
pattern suggesting that there is an early priming of tissue reactivity
even before demyelination is visible that probably already initiates
repair processes. The results also demonstrate that during each
phase of tissue destruction and repair there is a requirement for a
complex and exact orchestration of different signals which are also
region-specific in the CNS. Besides astrocytes, intrinsic microglia
also provide some of these signals.
Supporting Information
Figure S1 Laser microdissection. A) microdissected area of
the corpus callosum; B) microdissected area of the cortex; C)
Overview of coronal section with the dissected corpus callosum
and cortex. Brain sections were stained with cresyl violet.
(TIF)
Figure S2 Microglia and astrocytes during de- and
remyelination in the corpus callosum and the cortex.
Representative sections show microglia in the corpus callosum (cc)
(A–D) and the cortex (ctx) (E–H), stained with fluorescein coupled
anti-RCA-1 (in green). The peak of microgliosis was observed at
week 4.5 in both the corpus callosum and the cortex (B, F).
Astrogliosis is shown in the corpus callosum (I–L) and the cortex
(M–P), stained with anti-GFAP and Alexa 555 secondary
antibodies (in red). In untreated animals numerous GFAP positive
cells are found in the corpus callosum (I) in contrast to only few
GFAP positive cells in the cortex (M). Upon cuprizone treatment
reactive astroglia appear in the cortex and in the corpus callosum.
At week 4.5 hypertrophic astrocytes are abundantly detected in
both areas (J, N). At weeks 5 and 6 astroglia are still presented in
large numbers in the corpus callosum and the cortex, however, the
shape of astrocytes alters and their processes become thinner (K,
L, O, P). For nucleus staining, slides were counterstained by
DAPI.
(TIF)
Table S1 TaqManH Gene Expression Assays (Applied
Biosystems, USA) were used to investigate mRNA
expression of different growth factors.
(DOC)
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